A Review on Pharmacological and Therapeutical Insight of Satranidazole for Colon Targeting in the treatment of Colonic Diseases
Abstract
Drugs targeting the colonic environment to treat various colonic diseases are the major challenges recently. Various drugs are available in the markets to targeting to the colonic region to treat diseases but due to premature drug releases, target specificity, the low concentration at the target site with high adverse effects which increase patients’ compliance day by day. Satranidazole is a promising drug that is particularly targeting the colonic environment and can break down microorganism DNA to involve the treatment of several diseases such as inflammatory bowel diseases subdivided Ulcerative colitis, Crohn’s disease, amoebiasis, chronic diarrhea, and reduction of pain due to inflammation. Conventional drug delivery of Satranidazole has some disadvantages such as target specificity, high dosing frequency, low therapeutic efficacy, and high adverse effects that can be overcome through targeted drug delivery systems. Satranidazole is successfully showing the efficacy against aerobic, microaerophilic as well as anaerobic bacterial and reduction of inflammation of inflammatory bowel diseases subdivided as Ulcerative colitis and Crohn’s disease. It is a much more potent drug than metronidazole and has fewer adverse effects. Satranidazole is more convenient for oral administration compared to other routes of administration to show activity. Researchers are giving much more attention to targeted drug delivery systems of Satranidazole to show high therapeutic activity with fewer side effects. The current review focus on the pharmacological and therapeutical insight of Satranidazole in the treatment of colonic diseases and recent advancement and the future aspects of Satranidazole targeting various diseases.
Keywords: Satranidazole, Inflammatory bowel diseases, Ulcerative colitis, Crohn’s disease, Amoebiasis, Targeted drug delivery system, Future advancement, Colonic drug delivery systems.
Keywords:
Satranidazole, Inflammatory bowel diseases, Targeted drug delivery system, Future advancement, Colonic drug delivery systems.DOI
https://doi.org/10.22270/jddt.v12i1-S.5348References
Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman medical journal. 2010 Apr; 25(2):79-87. DOI: http:/doi.org/10.5001/omj.2010.24 https://doi.org/10.5001/omj.2010.24
Cui M, Zhang M, Liu K. Colon-targeted drug delivery of polysaccharide-based nanocarriers for the synergistic treatment of inflammatory bowel disease: A review. Carbohydrate Polymers. 2021 Nov 15; 272:118530. https://doi.org/10.1016/j.carbpol.2021.118530
Liu L, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via the oral route. Biomaterials. 2003 Aug 1; 24(19):3333-3343. https://doi.org/10.1016/S0142-9612(03)00213-8
Nicholas ME, Panaganti S, Prabakaran L, Jayveera KN. Novel colon-specific drug delivery system: A review. International Journal of Pharmaceutical Sciences and Research. 2011 Oct 1; 2(10):2545-2561.
Pawar HA, Joshi PR. Development and validation of a discriminating in vitro dissolution method for oral formulations containing Satranidazole. International Journal of Spectroscopy. 2014:1-8. https://doi.org/10.1155/2014/624635
Zahoor A, Knight RC, Whitty P, Edwards DL. Satranidazole: mechanism of action on DNA and structure-activity correlations. Journal of Antimicrobial Chemotherapy. 1986 Jul 1; 18(1):17-25. https://doi.org/10.1093/jac/18.1.17
Gowrishankar R, Phadke RP, Oza SD, Tulwalker S. Satranidazole: experimental evaluation of activity against anaerobic bacteria in vitro and in animal models of anaerobic infection. Journal of Antimicrobial Chemotherapy. 1985 Apr 1; 15(4):463-470. https://doi.org/10.1093/jac/15.4.463
Rathi PB, Kale M, Jouyban A. Thermodynamic Modeling and Solubility Study of Satranidazole in Different Monosolvents at Different Temperatures. Journal of Chemical & Engineering Data. 2021 Sep 1; 66(10):3745-56. https://doi.org/10.1021/acs.jced.1c00385
Rose MF, Peruboina R, Hamid HE, Parthipan P. Development of new RP-HPLC method for the simultaneous estimation of Satranidazole and Oflaxacin pharmaceutical dosage form. Indian Journal of Research in Pharmacy and Biotechnology. 2017; 5(5):325-328.
Malathi DC, AnushaBommasani RP. Self-medicated, satranidazole induced fixed drug eruption: a case report. International Journal of Basic & Clinical Pharmacology. 2020 Dec; 9(12):1903-1905. https://doi.org/10.18203/2319-2003.ijbcp20205131
Dhat S, Pund S, Kokare C, Sharma P, Shrivastava B. Risk management and statistical multivariate analysis approach for design and optimization of satranidazole nanoparticles. European Journal of pharmaceutical sciences. 2017 Jan 1; 96:273-83. https://doi.org/10.1016/j.ejps.2016.09.035
Zahoor A, Knight RC, Whitty P, Edwards DL. Satranidazole: mechanism of action on DNA and structure-activity correlations. Journal of Antimicrobial Chemotherapy. 1986 Jul 1; 18(1):17-25. https://doi.org/10.1093/jac/18.1.17
Sanmukhani J, Shah V, Baxi S, Tripathi C. Fixed drug eruption with ornidazole having cross-sensitivity to secnidazole but not to other nitro-imidazole compounds: A case report. British journal of clinical pharmacology. 2010 Jun; 69(6):703-704. https://doi.org/10.1111/j.1365-2125.2010.03651.x
Parmar DM, Jadav SP. The concept of personal drugs in the undergraduate pharmacology practical curriculum. Indian Journal of Pharmacology. 2007 May 1; 39(3):165. https://doi.org/10.4103/0253-7613.33438
Krishna U, Gupta K, Vaidya AB, Desai J, Paul T, Sheth UK. Single dose therapy for trichomonal vaginitis with satranidazole (Go. 10213)-phase 2 study with a new antiprotozoal agent. J. Ob/Gyn India. 1986; 36:688-692.
Chandra D, Yadav IK, Jaiswal D, Ghosh N, Singh HP, Mishra A, Bhattacharya A, Bajpai M, Jain DA. Formulation and evaluation of satranidazole microspheres for colon targeted drug delivery. J Pharm Res. 2009 Jul; 2(7):1230-1233.
Tiwari A, Ramteke S, Dahima R, Shukla R. Preparation and characterization of satranidazole loaded calcium pectinate microbeads for colon specific delivery; Application of response surface methodology. Current Nanoscience. 2011 Aug 1; 7(4):608-15. https://doi.org/10.2174/157341311796196871
Jagtap J, Patil M, Patil V. Development and in‐vitro evaluation of colon-specific satranidazole tablet for the treatment of amoebiasis. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm. 2014 Aug 28; 7(2): 1-7. https://doi.org/10.4103/0973-8398.115952
Disha SN, Raju S, Govind RS, Dev JA. An Investigation on Colon Drug Delivery System for Satranidazole Tablet. International Journal of Research in Pharmacy & Science. 2013 Apr 1; 3(2): 161-182.
Pawar HA, Joshi PR. Development and evaluation of taste masked granular formulation of satranidazole by melt granulation technique. Journal of pharmaceutics. 2014; 8(6):78-84. https://doi.org/10.1155/2014/789676
Bansal K, Rawat MK, Jain A, Rajput A, Chaturvedi TP, Singh S. Development of satranidazole mucoadhesive gel for the treatment of periodontitis. Aaps Pharmscitech. 2009 Sep; 10(3):716-723. https://doi.org/10.1208/s12249-009-9260-z
Pradesh A et al. Comparative Evaluation of the Clinical efficacy of 3% Satranidazole and 1% Ornidazole (OrnigreatTM) gel through local drug delivery system in the treatment of Chronic periodontitis. Research J Pharm and Tech. 2020; 13(8): 3675-3680. https://doi.org/10.5958/0974-360X.2020.00650.2
Chandra D, Yadav IK, Jaiswal D, Ghosh N, Singh HP, Mishra A, Bhattacharya A, Bajpai M, Jain DA. Formulation and evaluation of satranidazole microspheres for colon targeted drug delivery. J Pharm Res. 2009 Jul; 2(7):1230-1233.
Tirumala K et al. Formulation and Characterization of Satranidazole Loaded Polymeric Nanoparticles. International Journal of Pharmacy and Biological Science. 2019; 9(2):360-370.
Chandra D, Yadav IK, Jaiswal D, Ghosh N, Singh HP, Mishra A, Bhattacharya A, Bajpai M, Jain DA. Formulation and evaluation of Satranidazole microspheres for colon targeted drug delivery. J Pharm Res. 2009 Jul; 2(7):1230-1233.
Saboktakin MR, Tabatabaie RM, Maharramov A, Ramazanov MA. Synthesis and characterization of biodegradable chitosan beads as nano-carriers for local delivery of satranidazole. Carbohydrate Polymers. 2010 Jul 7; 81(3):726-731. https://doi.org/10.1016/j.carbpol.2010.03.047
Singh PR, Kumar VI. Preparation and characterization of Poly (Ɛ-Caprolactone) Nanosuspension containing Satranidazole. World Journal of Pharmaceutical research. 2013 Oct; 3(1):1460-1472.
Priyanka N, Kalra N, Saquib S, Kudyar N, Malgaonkar N, Jain H, Pradeep AR. Clinical and microbiological efficacy of 3% satranidazole gel as a local drug delivery system in the treatment of chronic periodontitis: A randomized, controlled clinical trial. Contemporary clinical dentistry. 2015 Jul; 6(3):364-372. https://doi.org/10.4103/0976-237X.161891
Kaur S, Narang RK, Aggarwal G. Formulation and development of colon-targeted mucopenetrating metronidazole nanoparticles. Tropical Journal of Pharmaceutical Research. 2017 Jun 2; 16(5):967-973. https://doi.org/10.4314/tjpr.v16i5.1
Jadhav VY, Gandhi SV, Dhavale ND, Sabnis SS. RP-HPLC determination of nitazoxanide in bulk and different tablet formulations. Eurasian Journal of Analytical Chemistry. 2008; 3(3):318-323
Published
Abstract Display: 985 
PDF Downloads: 890 PDF Downloads: 356 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.